The clinical application of stem cell transplantation has been standardized
On the 7th national diabetic foot symposium that was held in Beijing on October 21th to October 22th, the expert consensus on the treatment of lower limb ischemia by autologous stem cell transplantation was published by the stem cell engineering professional committee of Chinese medical association, which is the first standardized plan to guide clinical stem cell transplantation treatment in China.
According to Consensus, the indications of autologous stem cell transplantation include patients with chronic lower limb ischemic disease caused by various reasons, ineffective conservative treatment like medicine therapy, and inability to perform arterial bypass graft or interventional therapy (balloon dilation or stent intervention); Patients who are with tumors or significantly elevated levels of tumor markers in their blood within the past 5 years; Patients with severe cardiac, pulmonary, hepatic and renal insufficiency, or severe systemic infection, and patients with major artery occlusion such as main and iliac arteries, etc. are all contraindicated for this treatment. The consensus also made clear requirements on personnel qualifications, perioperative management, stem cell preparation, methods of transplantation and postoperative evaluation of the treatment technology.
According to information that lower limb ischemia is a common clinical symptoms, atherosclerosis occlusion, diabetic foot and other major causes. Autologous stem cell transplantation (autologous stem cell transplantation) is a novel therapy that can improve the symptoms of limb ischemia by injecting autologous stem cells locally in vitro and promoting the formation of new blood vessels at the ischemic site through its differentiation. It is reported that at present, autologous stem cell transplantation has been used to treat more than 8000 patients with lower limb ischemia in China, with the clinical effective rate of more than 80%.
The capital university of medical sciences institute of vascular surgery, deputy director of the valley, yongquan said, so many countries think this is controversial for the ethical and moral issues and safety of stem cell transplantation, but the "consensus" is related to the autologous stem cells, there is no risk of immune rejection of allogeneic stem cells, embryonic stem cells of ethical questions, there is no heterogeneous serum levels of pollution and risk of genetic mutations, etc.
Wang zhonghao, a member of the Chinese academy of sciences and director of the institute of vascular surgery at capital medical university, said that autologous stem cell transplantation for chronic ischemic diseases of the lower limbs is a mature therapy confirmed by clinical experiments at home and abroad. In order to ensure the clinical efficacy, the screening of indications and standardized operation are important preconditions.
- April 8, 2018In the past 10 years, Tumor immunotherapy technology has been a major development, and gradually applied to clinical trials. As one of the hopes of the ultimate capture of the tumor, immunotherapy has...view
- March 25, 2019March 5, 2019 / Bio Valley BIOON / -- Cancer immunotherapy giant Merck & Co recently announced that the European Medicines Agency (EMA) Human Pharmaceutical Products Committee (CHMP) has issued po...view
- May 16, 2019ALIT Life Science focuses on providing advanced laboratory instrument, technology and laboratory concept for life science field. Its head office, research and development center are in Shanghai China....view